arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Edwards Lifesciences Corp

EW
$88.81 ▲ +0.48 (+0.54%) at close
Healthcare ·Orthopedic, Prosthetic & Surgical Appliances & Supplies ·USOrthopedic, Prosthetic & Surgical Appliances & Supplies
72 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Edwards Lifesciences Corp shows strong fundamentals with top-quartile Profit Margin (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $51.2B
Dividend Yield
Revenue Growth 13.6%
Op. Margin 29.5%
ROIC 2.1%
FCF / Share $1.01
Trailing P/E 211.5x
Price / Book 4.8x
FCF Yield 1.1%
Debt / Equity 0.06
info Valuation on last close. End-of-day price, Sep 22, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.74B
↑ +13.6%
Net Income Profit after all expenses
$241.90M
↓ -27.4%
Operating Margin Operating profit as % of sales
29.5%
↑ +1.8% 77th
FCF / Share Free cash flow per share
$1.01
↑ +2886.0%
Long-Term Debt Long-term obligations
$598.70M
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
80
Returns
69
Financial Health
90
Cash Quality
74

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 19 years · 72 quarters